MRNA Moderna
- 121.875
- -0.815-0.66%
Moderna News
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
The Food and Drug Administration (FDA) notified Moderna Inc (NASDAQ:MRNA) on Friday that its review of a new vaccine has been delayed.The agency, citing administrative constraints, does not expect to
Sector Update: Health Care Stocks Edge Higher Premarket Friday
Health care stocks were edging higher premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) recently up 0.4%. Novavax (NVAX) skyrocketed
FDA Delays Decision on Moderna RSV Shot by 3 Weeks -- Barrons.com
By Josh Nathan-Kazis The Food and Drug Administration has pushed back the release of its decision on approval of Moderna's respiratory syncytial virus vaccine by up to three weeks due to "administrat
Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
By Colin Kellaher Moderna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's proposed vaccine for respiratory syncytial virus, or
FDA Delays Approval of Moderna's RSV Vaccine
07:25 AM EDT, 05/10/2024 (MT Newswires) -- FDA Delays Approval of Moderna's RSV Vaccine Price: 119.50, Change: -3.19, Percent Change: -2.60
Moderna said the US Food and Drug Administration will not complete the review of “mRNA-1345” before May 12. Moderna fell 1.5% before the market.
Moderna said the US Food and Drug Administration will not complete the review of “mRNA-1345” before May 12. Moderna fell 1.5% before the market.
FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12
FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12
Moderna Says FDA Delayed RSV Vaccine Approval to End of May
Moderna said the Food and Drug Administration has delayed the approval of its vaccine for respiratory syncytial virus to the end of May due to "administrative constraints" at the agency. The FDA was expected to make a decision on the RSV shot on Sunday. The agency has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said in a release.
Moderna Announces Update on Investigational RSV Vaccine
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024Agency has indicated it expects to complete the review by end of
US FDA Pushes Decision on Moderna's RSV Vaccine to End of This Month
The coronavirus hasn't disappeared yet! A new “FlIRt variant family” is spreading in the US...
① According to CDC data, the main variant of transmission in the US today is the “FlIRT” family, led by KP.2; ② KP.2 accounts for 25%; ③ medical experts warn that fLiRT has a more obvious transmission advantage and may trigger a new wave of COVID-19.
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Deutsche Bank Raises Moderna's Price Target to $85 From $70
Moderna (MRNA) has an average rating of outperform and price targets ranging from $60 to $310, according to analysts polled by Capital IQ. Price: 124.37, Change: +2.48, Percent Change: +2.03
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Moderna's Promise of MRNA Undercut by New RSV Vaccine
Novo Nordisk (NVO.US) invests $600 million to join Metaphor Biotech to build a new chapter in obesity treatment
Novo Nordisk (NVO.US), the manufacturer of popular drugs Ozempic and Wegovy, announced a new research agreement with biotech company Metaphor Biotechnology. The partnership was supported by Flagship Pioneering, which is also the venture capital company behind US vaccine manufacturer Moderna (MRNA.US). Under the agreement, Novo Nordisk agreed to pay up to $600 million to develop the next generation of obesity treatments.
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Novo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster -- Barrons.com
By Josh Nathan-Kazis Novo Nordisk has ridden the monster wave of enthusiasm over Wegovy, its once-weekly obesity shot, to become Europe's most valuable company. Now, it says it is beginning work on a
Moderna's MRNA Dreams Meet Reality With First Post-Covid Shot
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
Analysis
Price Target
No Data
